High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Yost, Shawn E ^a,b   Pastorino, Sandra ^a,c   Rozenzhak, Sophie ^b   Smith, Erin N ^b   Chao, Ying S ^a,c   Jiang, Pengfei ^a,c   Kesari, Santosh ^a,c,d   Frazer, Kelly A ^a,b,d   Harismendy, Olivier ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADY CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER LOCALIZATION; CASE REPORT; CELL ADHESION; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOSS; GENETIC CONSERVATION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR PATHOLOGY; MOUSE; MUTATIONAL ANALYSIS; MUTATOR GENE; NONHUMAN; ONCOGENE; PIK3R1 GENE; PTEN GENE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; EXOME; GLIOBLASTOMA; HUMANS; MICE; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 84874134046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056185     Document Type: Article

References (48)

1. Varela I, Tarpey P, Raine K, Huang D, Ong CK, et al. (2011) Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469: 539-542 doi:10.1038/nature09639.
2. Jones S, Wang T-L, Shih I-M, Mao T-L, Nakayama K, et al. (2010) Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma. Science (New York, N.Y.) 330: 228-31 doi:10.1126/science.1196333.
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 307-603.
4. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
5. Ng KP, Hillmer AM, Chuah CTH, Juan WC, Ko TK, et al. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18: 521-528.
6. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, et al. (2011) BRAF Mutations in Hairy-Cell Leukemia. New England Journal of Medicine 364: 2305-2315 doi:10.1056/NEJMoa1014209.
7. Wen PY, Kesari S, (2008) Malignant Gliomas in Adults. New England Journal of Medicine 359: 492-507 doi:10.1056/NEJMra0708126.
8. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812 doi:1164382 [pii]10.1126/science.1164382.
9. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 Mutations in Gliomas. New England Journal of Medicine 360: 765-773 doi:10.1056/NEJMoa0808710.
10. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, et al. (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: i. Acta Neuropathologica 120: 707-718 doi:10.1007/s00401-010-0781-z.
11. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
12. Pastor DM, Poritz LS, Olson TL, Kline CL, Harris LR, et al. (2010) Primary cell lines: false representation or model system? a comparison of four human colorectal tumors and their coordinately established cell lines. International journal of clinical and experimental medicine 3: 69-83.
13. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391-403.
14. Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, et al. (2005) Influence of in vivo growth on human glioma cell line gene expression: Convergent profiles under orthotopic conditions. Proceedings of the National Academy of Sciences of the United States of America 102: 8287-8292.
15. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, et al. (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature advance on.
16. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature advance on.
17. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, et al. (2012) Clonal Architecture of Secondary Acute Myeloid Leukemia. New England Journal of Medicine. doi:10.1056/NEJMoa1106968.
18. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. (2012) Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. New England Journal of Medicine 366: 883-892 doi:10.1056/NEJMoa1113205.
19. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, et al. (2010) Inferring tumor progression from genomic heterogeneity. Genome Research 20: 68-80.
20. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, et al. (2011) Tumour evolution inferred by single-cell sequencing. Nature 472: 90-94.
21. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, et al. (2012) Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proceedings of the National Academy of Sciences 109: 3041-3046.
22. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, et al. (2011) Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma. Cancer Cell 20: 810-817.
23. Little SE, Popov S, Jury A, Bax DA, Doey L, et al. (2012) Receptor Tyrosine Kinase Genes Amplified in Glioblastoma Exhibit a Mutual Exclusivity in Variable Proportions Reflective of Individual Tumor Heterogeneity. Cancer Research 72: 1614-1620.
24. Jeuken JW, Sprenger SH, Wesseling P, Bernsen HJ, Suijkerbuijk RF, et al. (2000) Genetic reflection of glioblastoma biopsy material in xenografts: characterization of 11 glioblastoma xenograft lines by comparative genomic hybridization. Journal of neurosurgery 92: 652-8 doi:10.3171/jns.2000.92.4.0652.
25. Hodgson JG, Yeh R-F, Ray A, Wang NJ, Smirnov I, et al. (2008) Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro-Oncology 11: 477-487 doi:10.1215/15228517-2008-113.
26. Clark MJ, Homer N, O'Connor BD, Chen Z, Eskin A, et al. (2010) U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line. PLoS Genet 6: e1000832.
27. Masramon L, Vendrell E, Tarafa G, Capellà G, Miró R, et al. (2006) Genetic instability and divergence of clonal populations in colon cancer cells in vitro. Journal of Cell Science 119: 1477-1482.
28. Pandita A, Aldape KD, Zadeh G, Guha A, James CD, (2004) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes, chromosomes & cancer 39: 29-36 doi:10.1002/gcc.10300.
29. Ding L, Ellis MJ, Li S, Larson DE, Chen K, et al. (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464: 999-1005 doi:10.1038/nature08989.
30. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, et al. (2007) A Perivascular Niche for Brain Tumor Stem Cells. Cancer Cell 11: 69-82.
31. Leuraud P, Taillandier L, Aguirre-Cruz L, Medioni J, Criniere E,et al. (n.d.) Correlation between genetic alterations and growth of human malignant glioma xenografted in nude mice. Br J Cancer 89: 2327-2332.
32. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43: 491-498.
33. Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, et al. (2009) VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25: 2283-2285 doi:btp373 [pii]10.1093/bioinformatics/btp373.
34. Fraley C, Raftery A (2007) MCLUST Version 3 for R: Normal Mixture Modeling and Model-Based Clustering.
35. Sathirapongsasuti JF, Lee H, Horst BAJ, Brunner G, Cochran AJ, et al. (2011) Exome Sequencing-Based Copy-Number Variation and Loss of Heterozygosity Detection: ExomeCNV. Bioinformatics (Oxford, England) 27: 2648-2654 doi:10.1093/bioinformatics/btr462.
36. Gnirke A, Melnikov A, Maguire J, Rogov P, LeProust EM, et al. (2009) Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol 27: 182-189 doi:nbt.1523 [pii]10.1038/nbt.1523.
37. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science (New York, N.Y.) 318: 1108-13 doi:10.1126/science.1145720.
38. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet Chapter 10: Unit 10 11. doi:10.1002/0471142905.hg1011s57.
39. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. (2008) Nature. 455: 1061-8 doi:10.1038/nature07385.
40. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, et al. (2012) VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Research.
41. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183.
42. Schulte A, Günther HS, Martens T, Zapf S, Riethdorf S, et al. (2012) Glioblastoma Stem-like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration. Clinical Cancer Research 18: 1901-1913.
43. Clark MJ, Chen R, Lam HYK, Karczewski KJ, Chen R, et al. (2011) Performance comparison of exome DNA sequencing technologies. Nat Biotech 29: 908-914.
44. Dong X, Guan J, English JC, Flint J, Yee J, et al. (2010) Patient-Derived First Generation Xenografts of Non-Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy. Clinical Cancer Research 16: 1442-1451 doi:10.1158/1078-0432.CCR-09-2878.
45. Dancey JE, Bedard PL, Onetto N, Hudson TJ, (2012) The Genetic Basis for Cancer Treatment Decisions. Cell 148: 409-420.
46. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, et al. (2010) Development of personalized tumor biomarkers using massively parallel sequencing. Science translational medicine 2: 20ra14 doi:10.1126/scitranslmed.3000702.
47. Lathia JD, Heddleston JM, Venere M, Rich JN, (2011) Deadly Teamwork: Neural Cancer Stem Cells and the Tumor Microenvironment. Cell Stem Cell 8: 482-485.
48. Krzywinski MI, Schein JE, Birol I, Connors J, Gascoyne R, et al. (2009) Circos: An information aesthetic for comparative genomics. Genome Research.